ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)
August 10, 2021Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is providing an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008) (NCT03684785). -
Ipsen and Exicure to develop therapies for neurodegenerative disorders
August 04, 2021Ipsen and Exicure have entered an exclusive partnership agreement for the research, development and marketing of new spherical nucleic acids (SNAs) for the potential treatment of Huntington’s disease and Angelman syndrome. -
Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases
February 21, 2019Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs.... -
Exicure Announces Positive Phase 1 Results for Lead Immuno-Oncology Asset
September 21, 2018Exicure announced Phase 1 results for AST-008, an SNA consisting of toll-like receptor 9 (TLR9) agonists designed for immuno-oncology applications.
Pharma Sources Insight January 2025
